c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Productos de "c-Met / HGFR"
Ordenar por
Golvatinib
CAS:Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFórmula:C33H37F2N7O4Pureza:98.24% - ≥95%Forma y color:SolidPeso molecular:633.69MK-8033
CAS:MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Fórmula:C25H21N5O3SPureza:97.16%Forma y color:SolidPeso molecular:471.53MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Fórmula:C26H23N7OPureza:98%Forma y color:SolidPeso molecular:449.51Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C31H29FN4O5Pureza:99.77% - 99.95%Forma y color:SolidPeso molecular:556.58PHA-665752
CAS:PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Fórmula:C32H34Cl2N4O4SPureza:97.01% - 99.35%Forma y color:SolidPeso molecular:641.61MGCD-265 analog
CAS:Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Fórmula:C26H20FN5O2S2Pureza:98.06% - 98.68%Forma y color:SolidPeso molecular:517.6Ref: TM-T6351
2mg35,00€5mg52,00€10mg85,00€25mg164,00€50mg255,00€100mgA consultar1mL*10mM (DMSO)62,00€AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Fórmula:C22H17N5O2Pureza:98.56%Forma y color:SolidPeso molecular:383.4Tepotinib hydrochloride(1 : x)
CAS:Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14Fórmula:C29H29ClN6O2Pureza:99.81%Forma y color:SolidPeso molecular:529.04Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Fórmula:C23H19Cl2FN6OPureza:98.80%Forma y color:SolidPeso molecular:485.34Ref: TM-T4260
1mg44,00€2mg55,00€5mg70,00€10mg87,00€25mg145,00€50mg258,00€100mg430,00€500mg998,00€1mL*10mM (DMSO)97,00€c-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Fórmula:C17H14N8SPureza:98.77%Forma y color:SolidPeso molecular:362.41Ref: TM-T10655
1mg85,00€5mg172,00€10mg236,00€25mg398,00€50mg588,00€100mg838,00€1mL*10mM (DMSO)188,00€Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H17FN6OPureza:99.24%Forma y color:SolidPeso molecular:412.42Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H21Cl2FN6O2Pureza:99.77%Forma y color:SolidPeso molecular:503.36Ref: TM-T8825
2mg35,00€5mg49,00€10mg69,00€25mg115,00€50mg177,00€100mg283,00€200mg378,00€1mL*10mM (DMSO)56,00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Forma y color:SolidPeso molecular:632.65Ref: TM-T3113
2mg39,00€5mg57,00€10mg79,00€25mg133,00€50mg207,00€100mg354,00€500mg848,00€1mL*10mM (DMSO)79,00€Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Fórmula:C34H29ClF2N6O5Pureza:98%Forma y color:SolidPeso molecular:675.08Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Fórmula:C27H23FN4O4SPureza:99.39%Forma y color:SolidPeso molecular:518.56Ref: TM-T13108
1mg50,00€5mg106,00€10mg158,00€25mg258,00€50mg379,00€100mg538,00€200mg733,00€1mL*10mM (DMSO)134,00€JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Fórmula:C20H12F2N6Pureza:98.84% - 99.52%Forma y color:SolidPeso molecular:374.35Ref: TM-T15617
1mg63,00€2mg89,00€5mg137,00€10mg210,00€25mg424,00€50mg627,00€100mg893,00€500mg1.786,00€1mL*10mM (DMSO)153,00€Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Forma y color:LiquidPeso molecular:145.2 kDaAltiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:98.98% - 99.39%Forma y color:SolidPeso molecular:510.46BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFórmula:C17H15N5Pureza:98.98%Forma y color:SolidPeso molecular:289.33Ref: TM-T7900
1mg50,00€5mg97,00€10mg170,00€25mg306,00€50mg444,00€100mg620,00€200mg835,00€1mL*10mM (DMSO)114,00€
